Nephrology in October 2026: FDA approves ravulizumab for IgAN, plus ORIGIN 3, RAINIER, TELIGAN, and ATTACK data from Kidney Week.
News|Articles|March 4, 2025
Nephrology Month in Review: February 2025
Author(s)Abigail Brooks, MA, Patrick Campbell
The nephrology month in review spotlights HCPLive’s coverage of renal trial developments, xenotransplant, new AKI guidance, and research about dialysis.
Advertisement
Advertisement
Building on a strong start to 2025 in January, February kept the field of
Related to this article
IgAN late-breakers led the meeting, alongside new data on aspirin, dialysis access, donor pregnancy, potassium, and depression.
Carla Nester, MD, discusses sustained proteinuria reduction and kidney function findings through 76 weeks of pegcetacoplan treatment.
In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.
Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.
Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.
Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.
Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.
Advertisement
Advertisement